Patents by Inventor Alison Evelynn Ondrus

Alison Evelynn Ondrus has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • EPSTEIN-BARR VIRUS ANTIBODIES AND USES THEREOF
    Publication number: 20230159626
    Abstract: Disclosed herein are antibodies or immunogenic fragments thereof that specifically bind to Epstein-Barr virus (EBV) glycoprotein 350 (gp350) or 220 or one or more epitopes of EBV gp350 and neutralize EBV infection. Also disclosed are immunogenic peptides comprising one or more gp350 epitopes, EBV antibody-small molecule conjugates and pharmaceutical compositions comprising the antibody or an immunogenic fragment thereof, one or more epitopes of EBV gp350, one or more immunogenic peptides, or the EBV antibody-small molecule conjugate. The antibodies, epitopes, immunogenic peptides, conjugates, and pharmaceutical compositions can be used to treat or prevent EBV infections and EBV-associated conditions and diseases.
    Type: Application
    Filed: July 29, 2022
    Publication date: May 25, 2023
    Applicants: CITY OF HOPE, CALIFORNIA INSTITUTE OF TECHNOLOGY
    Inventors: Javier Gordon OGEMBO, Lorraine Zvichapera MUTSVUNGUMA, Alison Evelynn ONDRUS
  • Epstein-Barr virus antibodies and uses thereof
    Patent number: 11401323
    Abstract: Disclosed herein are antibodies or immunogenic fragments thereof that specifically bind to Epstein-Barr virus (EBV) glycoprotein 350 (gp350) or 220 or one or more epitopes of EBV gp350 and neutralize EBV infection. Also disclosed are immunogenic peptides comprising one or more gp350 epitopes, EBV antibody-small molecule conjugates and pharmaceutical compositions comprising the antibody or an immunogenic fragment thereof, one or more epitopes of EBV gp350, one or more immunogenic peptides, or the EBV antibody-small molecule conjugate. The antibodies, epitopes, immunogenic peptides, conjugates, and pharmaceutical compositions can be used to treat or prevent EBV infections and EBV-associated conditions and diseases.
    Type: Grant
    Filed: April 27, 2018
    Date of Patent: August 2, 2022
    Assignees: CITY OF HOPE, CALIFORNIA INSTITUTE OF TECHNOLOGY
    Inventors: Javier Gordon Ogembo, Lorraine Zvichapera Mutsvunguma, Alison Evelynn Ondrus
  • EPSTEIN-BARR VIRUS ANTIBODIES AND USES THEREOF
    Publication number: 20200055924
    Abstract: Disclosed herein are antibodies or immunogenic fragments thereof that specifically bind to Epstein-Barr virus (EBV) glycoprotein 350 (gp350) or 220 or one or more epitopes of EBV gp350 and neutralize EBV infection. Also disclosed are immunogenic peptides comprising one or more gp350 epitopes, EBV antibody-small molecule conjugates and pharmaceutical compositions comprising the antibody or an immunogenic fragment thereof, one or more epitopes of EBV gp350, one or more immunogenic peptides, or the EBV antibody-small molecule conjugate. The antibodies, epitopes, immunogenic peptides, conjugates, and pharmaceutical compositions can be used to treat or prevent EBV infections and EBV-associated conditions and diseases.
    Type: Application
    Filed: April 27, 2018
    Publication date: February 20, 2020
    Inventors: Javier Gordon OGEMBO, Lorraine Zvichapera MUTSVUNGUMA, Alison Evelynn ONDRUS
  • Imidazo bicyclic iminium compounds as antitumor agents
    Patent number: 9611276
    Abstract: Compounds of formula I: are disclosed. The compounds are inhibitors of Hedgehog pathway activation and are useful in treating solid tumors.
    Type: Grant
    Filed: June 19, 2013
    Date of Patent: April 4, 2017
    Assignee: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY
    Inventors: James Chen, Tomoyo Sakata Kato, Alison Evelynn Ondrus